Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 3 clinical trials
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow

to 101 weeks with naxitamab and granulocyte-macrophage colony stimulating factor (GM-CSF). Patients will be followed for up to five years after first dose. Naxitamab, also known as hu3F8 is a

hu3f8
high-risk neuroblastoma
colony stimulating factor
bone marrow procedure
monoclonal antibodies
  • 156 views
  • 13 Mar, 2021
  • 31 locations
Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma Osteosarcoma and Other Solid Tumor Cancers

The purpose of this study is to test the safety of a study drug called humanized 3F8 bispecific antibody (Hu3F8-BsAb).

cyclophosphamide
methotrexate
iobenguane
cancer chemotherapy
vincristine
  • 3 views
  • 18 Mar, 2021
  • 1 location
Study of Chemoimmunotherapy for High-Risk Neuroblastoma

The purpose of this study is to find out whether an experimental drug called Hu3F8 can be given with the chemotherapy drugs irinotecan and temozolomide and another drug called GM-CSF. The

high-risk neuroblastoma
metastasis
mycn protein
temozolomide
colony stimulating factor
  • 30 views
  • 11 Apr, 2021
  • 1 location